실적분석 2026년 7월 31일

Moderna ($MRNA) Q2 2026 Earnings Analysis — After-Hours Decline on Norovirus Setback Despite Revenue Beat

Earnings Scorecard

Revenue: $145M (+2% YoY; consensus $103M) ✅ Beat

EPS: GAAP -$1.97 (consensus adjusted -$2.00 · not directly comparable due to differing bases)

Guidance: Maintained — reaffirmed 2026 revenue growth of up to 10%; slight improvement to full-year OpEx and year-end cash outlook

Stock reaction: After-hours -3.28% ($56.02) — as of 07-31 20:59 KST

What Went Well

Revenue beat: Q2 revenue of $145M came in well above the $103M consensus.

Accelerating cost discipline: R&D and SG&A each fell 7% and 6% respectively; full-year cost guidance improved by roughly $200M.

Approval momentum: The U.S. PDUFA target date for its seasonal flu vaccine (August 5) is approaching, alongside international product authorizations and contract wins.

Q2 total revenue of $145M edged up from $142M a year earlier and comfortably topped the $103M the market had been expecting. Geographic revenue — U.S. $87M and international $57M — reflected soft COVID-19 vaccine sales in the U.S. and South America being offset by a long-term strategic partnership supply agreement with the UK government, along with higher stand-by manufacturing and collaboration revenue.

On the cost side, cost of sales declined 22%, while R&D of $651M and SG&A of $216M were both lower year-on-year. The company lowered its 2026 R&D outlook to roughly $2.9B and cost of sales to roughly $1.7B, both below prior guidance, and raised its year-end cash and investments range to $4.7B–$5.2B, a roughly $200M upward revision.

On the pipeline, mFLUSIVA has received a unanimous recommendation from a U.S. advisory committee ahead of its August 5 PDUFA date, and the company continues to broaden its commercial footprint via international authorizations for mRESVIA and mNEXSPIKE, as well as a European joint procurement contract.

What Disappointed

Norovirus setback: The Phase 3 interim analysis of mRNA-1403 did not meet the prespecified early-success criteria.

Softer product sales: Net product revenue of $94M was below the prior-year $114M.

Losses and cash burn: Net loss of $782M; cash of $6.9B at end-June extended the quarterly downtrend.

The biggest disappointment was the Phase 3 interim readout for its norovirus vaccine candidate. It failed to clear the statistical bar for early success, and the company said it is preparing to enroll additional cohorts. The trial is continuing in a blinded fashion, but the prospect of timeline delays clearly weighed on the market.

Revenue composition is also worth flagging. While total revenue beat estimates, the more core net product line shrank year-on-year, with the upside driven largely by other revenue ($51M) tied to stand-by manufacturing and collaborations. Continued softness in COVID-19 vaccine demand in the U.S. and South America was the backdrop.

Profitability remains deeply in the red. Q2 net loss of $782M, or $1.97 per share, and cash and investments of $6.9B at end-June were down from $7.5B at end-March. In July, the company additionally paid a $950M litigation settlement related to a previously disclosed case, meaning hitting its year-end cash target now hinges on cost control and revenue delivery in the second half.

What Management Said

CEO Stéphane Bancel characterized Q2 as a quarter in which pipeline progress and balance-sheet strengthening were achieved together. He highlighted the lower full-year OpEx outlook and noted that the company is preparing for the potential U.S. approval of mFLUSIVA in the second half, along with key melanoma and propionic acidemia clinical readouts. The revenue guide was simply a reaffirmation of up to 10% growth versus the prior year — a tone weighted toward maintaining the target and managing costs and cash rather than an aggressive upward revision.

From a market perspective, the read-through may weigh pipeline timing and the quality of product revenue more heavily than the headline revenue surprise. Management indicated roughly 55% of second-half revenue is expected to land in Q3, with the U.S. and international split roughly 50/50. Cost savings and the higher year-end cash range are positive signals, but additional norovirus enrollment and the August flu vaccine approval decision will be the central pillars of investor confidence going forward.

Market Reaction and Watch Items

Despite a sizable revenue beat and improved cost outlook, the after-hours selloff suggests investors focused more on the failed norovirus Phase 3 interim analysis and the softness in net product sales than on the beat, which carried a heavy mix of one-off and collaboration revenue. Maintaining the full-year growth target was a relief, but the lack of an immediate fresh growth catalyst also appears to have fed the bearish sentiment.

Watch the outcome of the August 5 mFLUSIVA U.S. PDUFA date and whether initial commercial readiness is on track.

Track the size and timing of the additional norovirus cohort enrollment and the timing of the final efficacy readout.

Monitor whether the Q3-weighted revenue mix (~55% of the second half) translates into actual product sales and track progress toward the year-end cash range of $4.7B–$5.2B.